Skip to main content

CAPE – A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)

  • Aim: This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in pediatric patients with moderately to severely active CD who are treated as recommended in the product label. Requires quality of life questionnaire.  
  • Eligibility:  Children between the ages of 6 and 17 years with moderate to severe CD on Humira, 6MP, azathioprine or methotrexate.
  • Benefits: Stipend for subjects
  • More information: